Association between CYP17 T-34C rs743572 and breast cancer risk
Metrics: PDF 1507 views | HTML 2179 views | ?
Jing Sun1,*, Hong Zhang2,*, Meiyan Gao3,*, Zhishu Tang1, Dongyan Guo4, Xiaofei Zhang4, Zhu Wang5, Ruiping Li5, Yan Liu5, Wansen Sun5 and Xi Sun6
1Department of Shaanxi Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China
2Department of Neurology, Second Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, China
3Clinical Laboratory, Shaanxi Provincial Hospital of traditional Chinese medicine, Xi'an, Shaanxi, China
4College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China
5Department of Integrated Traditional Chinese and Western Medicine, Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, China
6Department of General Medicine, Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi'an, Shaanxi, China
*These authors contributed equally to this work
Wansen Sun, email: [email protected]
Xi Sun, email: [email protected]
Keywords: breast cancer; rs743572; polymorphism
Received: September 04, 2017 Accepted: December 18, 2017 Published: December 26, 2017
Association between CYP17 T-34C (rs743572) polymorphism and breast cancer (BC) risk was controversial. In order to derive a more definitive conclusion, we performed this meta-analysis. We searched in the databases of PubMed, EMBASE and Cochrane for eligible publications. Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to assess the strength of association between CYP17 T-34C polymorphism and breast cancer risk. Forty-nine studies involving 2,7104 cases and 3,4218 control subjects were included in this meta-analysis. In overall, no significant association between CYP17 T-34C polymorphism and breast cancer susceptibility was found among general populations. In the stratified analysis by ethnicity and source, significant associations were still not detected in all genetic models; besides, limiting the analysis to studies with controls in agreement with HWE, we also observed no association between CYP17 T-34C polymorphism and breast cancer risk. For premenopausal women, we didn't detect an association between rs743572 and breast cancer risk; however, among postmenopausal women, we observed that the association was statistically significant under the allele contrast genetic model (OR = 1.10, 95% CI = 1.03–1.17, P = 0.003), but not in other four models. In conclusion, rs743572 may increase breast cancer risk in postmenopausal individuals, but not in premenopausal folks and general populations.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.